0001062993-18-003711.txt : 20180911 0001062993-18-003711.hdr.sgml : 20180911 20180911212338 ACCESSION NUMBER: 0001062993-18-003711 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180910 FILED AS OF DATE: 20180911 DATE AS OF CHANGE: 20180911 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Wegman Mark N CENTRAL INDEX KEY: 0001405235 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-34236 FILM NUMBER: 181065856 MAIL ADDRESS: STREET 1: 43 OVERLOOK ROAD CITY: OSSINING STATE: NY ZIP: 10562 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BIOSPECIFICS TECHNOLOGIES CORP CENTRAL INDEX KEY: 0000875622 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 113054851 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 35 WILBUR ST CITY: LYNBROOK STATE: NY ZIP: 11563 BUSINESS PHONE: 5165937000 MAIL ADDRESS: STREET 1: 35 WILBUR STREET CITY: LYNBROOK STATE: NY ZIP: 11563 4 1 form4.xml STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES X0306 4 2018-09-10 0000875622 BIOSPECIFICS TECHNOLOGIES CORP BSTC 0001405235 Wegman Mark N C/O BIOSPECIFICS TECHNOLOGIES CORP. 35 WILBUR STREET LYNBROOK NY 11563 1 0 0 0 Common Stock, $0.001 par value 2018-09-10 4 S 0 5500 57.3102 D 66272 D Common Stock, $0.001 par value 2018-09-11 4 S 0 1000 58.655 D 65272 D The selling price of $57.3102 is reflective of the weighted average sale price of all transactions reported on this line. The prices for the transactions reported on this line range from $56.22 to $58.902. The reporting person undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. The selling price of $58.655 is reflective of the weighted average sale price of all transactions reported on this line. The prices for the transactions reported on this line range from $58.64 to $58.67. The reporting person undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. /s/ Mark Wegman by Carl A. Valenstein, attorney- in-fact 2018-09-11